Dr. Martens マネジメント
マネジメント 基準チェック /34
Dr. Martensの CEO はIje Nwokorieで、 Jan2025年に任命され、 の在任期間は 1.5年です。 の年間総報酬は£ 1.17Mで、 55.7%給与と44.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.16%を直接所有しており、その価値は£ 1.07M 。経営陣と取締役会の平均在任期間はそれぞれ2.7年と4.3年です。
主要情報
Ije Nwokorie
最高経営責任者
UK£1.2m
報酬総額
| CEO給与比率 | 55.65% |
| CEO在任期間 | 1.5yrs |
| CEOの所有権 | 0.2% |
| 経営陣の平均在職期間 | 2.7yrs |
| 取締役会の平均在任期間 | 4.3yrs |
経営陣の近況
Recent updates
ナラティブの更新 • Jun 29
DOCS: Future Returns Will Depend On Margins And Long Term Sustainability Partnership
Analysts have trimmed their price target on Dr. Martens, reflecting slightly lower fair value assumptions alongside modestly reduced projections for revenue growth, profit margins and future P/E multiples in their models. What’s in the News for Dr. Martens No recent news items for Dr. Martens are available from the specified primary sources at this time.
ナラティブの更新 • Jun 15
DOCS: Future Returns Will Rely On Steady Margins And Supportive Long Term Assumptions
Analysts have adjusted their price target on Dr. Martens, reflecting updated views on revenue growth, profit margins, the discount rate and future P/E assumptions. Together, these factors point to a refined estimate of the stock's underlying value in £ terms.ナラティブの更新 • Jun 01
DOCS: Future Returns Will Rely On Sustained Margins And Supportive Long Term Assumptions
Analysts have adjusted their price target on Dr. Martens to reflect updated assumptions around the discount rate, revenue growth, profit margin, and future P/E. This has led to a revised view of the stock's valuation in £ terms.分析記事 • May 28
We Think Dr. Martens' (LON:DOCS) Solid Earnings Are Understated
Investors signalled that they were pleased with Dr. Martens plc's ( LON:DOCS ) most recent earnings report. Looking...ナラティブの更新 • May 13
DOCS: Future Returns Will Depend On Steady Margins And Long Term Assumptions
Analysts have adjusted their price views on Dr. Martens, reflecting updated assumptions around discount rates, modestly different revenue growth and profit margin expectations, and a slightly altered future P/E multiple. Together, these factors feed into a refreshed £1.41 fair value estimate.ナラティブの更新 • Apr 28
DOCS: Future Returns Will Rely On Profit Focus And Stable Long Term Assumptions
Analysts have adjusted their price targets on Dr. Martens upward to £1.41, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E that are broadly in line with previous estimates but fine tuned to current views. Valuation Changes Fair Value: Modelled fair value remains at £1.41, with no change from the previous estimate.ナラティブの更新 • Apr 11
DOCS: Future Returns Will Rely On Profit Focus And Flat 2026 Revenue
Analysts have trimmed their price target on Dr. Martens to £1.41 from £1.41. They point to slightly higher assumed discount rates and modestly different revenue growth and profit margin expectations that keep the overall valuation level broadly unchanged.ナラティブの更新 • Mar 27
DOCS: Future Returns Will Rely On Profit Focus And Flat 2026 Revenue
Analysts have trimmed their fair value assumptions slightly, nudging the implied P/E closer to £19.95 and reflecting small updates to discount rate, revenue growth and profit margin expectations for Dr. Martens. What's in the News Issued earnings guidance for fiscal 2026 with revenue expected to be broadly flat on a constant currency basis as the company focuses on the quality of revenue and profitability (company guidance).ナラティブの更新 • Mar 13
DOCS: Future Returns Will Depend On Profit-Led Flat Revenue Guidance In 2026
Analysts have nudged their price target for Dr. Martens higher to £1.41, citing modest adjustments to assumptions about the discount rate, revenue, profit margin and future P/E in their updated models. What's in the News Dr. Martens issued earnings guidance for fiscal 2026, indicating that revenue on a constant currency basis is expected to be broadly flat as the company focuses on the quality of revenue and profitability (company guidance).ナラティブの更新 • Feb 27
DOCS: Future Returns Will Depend On Prioritising Profitability Over Near Term Revenue Expansion
Analysts have lifted their price target for Dr. Martens to £1.41, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin and future P/E that collectively point to a modestly improved risk and earnings profile. What's in the News Dr. Martens issued earnings guidance for fiscal 2026, indicating that revenue on a constant currency basis is expected to be broadly flat as the company focuses on the quality of revenue and profitability (company guidance).分析記事 • Feb 12
Dr. Martens' (LON:DOCS) Dividend Will Be £0.0085
Dr. Martens plc ( LON:DOCS ) has announced that it will pay a dividend of £0.0085 per share on the 9th of April. This...ナラティブの更新 • Feb 10
DOCS: Future Returns Will Depend On Expanding Reclaimed Leather Sustainability Collaboration
Analysts have adjusted their price targets for Dr. Martens modestly, reflecting revised assumptions around the discount rate, expected revenue growth, profit margins and a higher future P/E multiple, which together temper the valuation outlook while still supporting a measured premium on earnings. What's in the News Dr. Martens and materials company Gen Phoenix are marking four consecutive seasons of collaboration, extending their work with reclaimed leather under the Genix Nappa line.ナラティブの更新 • Jan 26
DOCS: Future Returns Will Rely On Reclaimed Leather Sustainability Partnership
Analysts have adjusted their price targets for Dr. Martens, reflecting updated assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple. Taken together, these factors point to a revised view of the shares' potential value, even though the fair value estimate remains at £1.41.ナラティブの更新 • Jan 11
DOCS: Future Returns Will Rely On Margins And Long Term Sustainability Partnership
Analysts have made a modest trim to their price target on Dr. Martens, reflecting slightly adjusted assumptions around discount rates, revenue growth, profit margins and future P/E, while still seeing the shares as aligned with an updated fair value of 0.8x. What's in the News Dr. Martens and Gen Phoenix mark four consecutive seasons of working together on reclaimed leather products under the Genix Nappa line, highlighting a multi year partnership rather than a short pilot or capsule approach (Key Developments).ナラティブの更新 • Dec 26
DOCS: Future Returns Will Depend On Margin Execution And Sustainability Delivery
Analysts have modestly adjusted their price target on Dr. Martens to 75 GBp, reflecting slightly higher long term revenue growth and profit margin assumptions while maintaining a broadly Neutral stance. Analyst Commentary Analyst commentary around Dr. Martens has remained measured, with the latest work reiterating a Neutral stance and a 75 GBp price target, signaling limited upside in the near term.ナラティブの更新 • Dec 12
DOCS: Modest Upside Outlook Will Hinge On Margin Recovery And Sustainability Expansion
The analyst price target for Dr. Martens has been modestly raised to £0.80 from £0.75, as analysts factor in slightly stronger expectations for revenue growth, profit margins, and future earnings multiples, while still maintaining a cautious overall stance. Analyst Commentary Recent Street research has reinforced a measured stance on Dr. Martens, with coverage reinstated at a neutral rating and a price target that sits below longer term historical trading levels.分析記事 • Dec 01
Shareholders Should Be Pleased With Dr. Martens plc's (LON:DOCS) Price
Dr. Martens plc's ( LON:DOCS ) price-to-earnings (or "P/E") ratio of 48.9x might make it look like a strong sell right...分析記事 • Nov 04
Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 26% Above Its Share Price
Key Insights The projected fair value for Dr. Martens is UK£1.13 based on 2 Stage Free Cash Flow to Equity Dr. Martens...
ナラティブの更新 • Oct 08
Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26
Analysts have raised their price target on Dr. Martens from £0.80 to £1.12 per share, citing expectations that 2025 will mark a turning point for the company and stating that market valuations do not yet reflect its long-term growth potential. Analyst Commentary Market watchers have offered mixed insights following the recent upgrade and price target increase for Dr. Martens.分析記事 • Aug 26
Returns On Capital Signal Tricky Times Ahead For Dr. Martens (LON:DOCS)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...ナラティブの更新 • Aug 19
Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26
Despite a notable downgrade in forecast revenue growth and a higher projected future P/E, analysts have nonetheless raised Dr. Martens’ consensus price target from £0.898 to £0.952. What's in the News The Board of Dr. Martens proposed a final dividend of 1.70 pence, maintaining the total dividend for fiscal year 2025 at 2.55 pence, equal to the prior year, pending shareholder approval.分析記事 • Aug 05
Is Dr. Martens plc (LON:DOCS) Trading At A 29% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Dr. Martens fair value estimate is UK£1.09 Dr. Martens...分析記事 • Jun 18
Dr. Martens (LON:DOCS) Has Announced That It Will Be Increasing Its Dividend To £0.017
Dr. Martens plc's ( LON:DOCS ) dividend will be increasing from last year's payment of the same period to £0.017 on 8th...分析記事 • Jun 15
Some Investors May Be Willing To Look Past Dr. Martens' (LON:DOCS) Soft Earnings
Dr. Martens plc's ( LON:DOCS ) stock was strong despite it releasing a soft earnings report last week. Our analysis...分析記事 • Apr 15
Dr. Martens (LON:DOCS) May Have Issues Allocating Its Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
新しいナラティブ • Mar 14
Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26
Strategic focus on premium positioning, demand planning, and cost reductions aims to enhance revenue, margins, and profitability.分析記事 • Dec 06
Earnings Tell The Story For Dr. Martens plc (LON:DOCS) As Its Stock Soars 27%
Dr. Martens plc ( LON:DOCS ) shareholders would be excited to see that the share price has had a great month, posting a...分析記事 • Dec 01
Dr. Martens plc (LON:DOCS) Half-Yearly Results: Here's What Analysts Are Forecasting For This Year
The investors in Dr. Martens plc 's ( LON:DOCS ) will be rubbing their hands together with glee today, after the share...分析記事 • Sep 21
Benign Growth For Dr. Martens plc (LON:DOCS) Underpins Stock's 30% Plummet
The Dr. Martens plc ( LON:DOCS ) share price has fared very poorly over the last month, falling by a substantial 30...分析記事 • Aug 20
Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 45% Undervaluation?
Key Insights Dr. Martens' estimated fair value is UK£1.31 based on 2 Stage Free Cash Flow to Equity Dr. Martens...分析記事 • Jul 20
Dr. Martens (LON:DOCS) Has Some Way To Go To Become A Multi-Bagger
What are the early trends we should look for to identify a stock that could multiply in value over the long term...分析記事 • Jun 19
There May Be Some Bright Spots In Dr. Martens' (LON:DOCS) Earnings
The market was pleased with the recent earnings report from Dr. Martens plc ( LON:DOCS ), despite the profit numbers...分析記事 • May 21
Dr. Martens plc's (LON:DOCS) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Dr. Martens plc ( LON:DOCS ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...分析記事 • Mar 27
The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...分析記事 • Mar 06
Dr. Martens (LON:DOCS) Has A Somewhat Strained Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Feb 08
Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 57% Above Its Share Price
Key Insights The projected fair value for Dr. Martens is UK£1.32 based on 2 Stage Free Cash Flow to Equity Dr. Martens...分析記事 • Jan 21
Dr. Martens plc's (LON:DOCS) Business And Shares Still Trailing The Market
With a price-to-earnings (or "P/E") ratio of 6.9x Dr. Martens plc ( LON:DOCS ) may be sending very bullish signals at...分析記事 • Jan 03
Dr. Martens' (LON:DOCS) Dividend Will Be £0.0156
Dr. Martens plc ( LON:DOCS ) has announced that it will pay a dividend of £0.0156 per share on the 2nd of February...分析記事 • Dec 13
Dr. Martens (LON:DOCS) Will Pay A Dividend Of £0.0156
Dr. Martens plc's ( LON:DOCS ) investors are due to receive a payment of £0.0156 per share on 2nd of February. This...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 29 2026 | UK£1m | UK£650k | UK£24m |
| Dec 29 2025 | n/a | n/a | UK£20m |
| Sep 28 2025 | n/a | n/a | UK£15m |
| Jun 28 2025 | n/a | n/a | UK£10m |
| Mar 30 2025 | n/a | n/a | UK£5m |
| Dec 30 2024 | n/a | n/a | UK£17m |
| Sep 29 2024 | n/a | n/a | UK£29m |
| Jun 29 2024 | n/a | n/a | UK£49m |
| Mar 31 2024 | UK£57k | n/a | UK£69m |
| Dec 31 2023 | n/a | n/a | UK£86m |
| Sep 30 2023 | n/a | n/a | UK£103m |
| Jun 30 2023 | n/a | n/a | UK£116m |
| Mar 31 2023 | UK£67k | n/a | UK£129m |
| Dec 31 2022 | n/a | n/a | UK£153m |
| Sep 30 2022 | n/a | n/a | UK£177m |
| Jun 30 2022 | n/a | n/a | UK£179m |
| Mar 31 2022 | UK£65k | n/a | UK£181m |
| Dec 31 2021 | n/a | n/a | UK£118m |
| Sep 30 2021 | n/a | n/a | UK£54m |
| Jun 30 2021 | n/a | n/a | UK£44m |
| Mar 31 2021 | UK£11k | n/a | UK£35m |
報酬と市場: Ijeの 総報酬 ($USD 1.56M ) は、 UK市場 ($USD 1.58M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Ijeの報酬は過去 1 年間で 20% 以上増加しました。
CEO
Ije Nwokorie (56 yo)
1.5yrs
在職期間
UK£1,168,000
報酬
Mr. Onyeije Ogueri Nwokorie, also known as Ije, is CEO & Director at Dr. Martens Limited since January 06, 2025. He was Chief Brand Officer at Dr. Martens plc since February 01, 2024. He is Independent Non...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Executive Director | 1.5yrs | UK£1.17m | 0.16% £ 1.1m | |
| CFO & Director | 2.2yrs | UK£820.00k | 0.035% £ 236.2k | |
| Interim Chief Operations Officer | no data | データなし | データなし | |
| Chief Technology Officer | no data | データなし | データなし | |
| Director of Investor Relations & Corporate Communications | no data | データなし | データなし | |
| Chief Legal Officer & Company Secretary | 2.1yrs | データなし | データなし | |
| Chief People Officer | no data | データなし | データなし | |
| Chief Digital Officer | 8.3yrs | データなし | データなし | |
| President of APAC | 6.8yrs | データなし | データなし | |
| Chief Commercial Officer | 3.2yrs | データなし | データなし | |
| Director of Sustainability | no data | データなし | データなし | |
| Head of Internal Audit & Risk | no data | データなし | データなし |
2.7yrs
平均在職期間
経験豊富な経営陣: DOCSの経営陣は 経験豊富 であると考えられます ( 2.7年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Executive Director | 1.5yrs | UK£1.17m | 0.16% £ 1.1m | |
| CFO & Director | 2.2yrs | UK£820.00k | 0.035% £ 236.2k | |
| Independent Non-Executive Director | 1.3yrs | UK£68.00k | 0.021% £ 143.0k | |
| Independent Non-Executive Director | 3.2yrs | UK£68.00k | 0.0080% £ 54.7k | |
| Non-Independent Non-Executive Director | 1.3yrs | データなし | データなし | |
| Independent Non-Executive Director | 5.5yrs | UK£68.00k | 0% £ 0 | |
| Independent Non-Executive Director | 5.5yrs | UK£96.00k | 0.010% £ 71.0k | |
| Representative Non-Independent Non-Executive Director | 5.5yrs | データなし | データなし | |
| Senior Independent Non-Executive Director | 5.5yrs | UK£101.00k | 0.0048% £ 32.9k | |
| Chair of the Board | 10.8yrs | UK£342.00k | 0.82% £ 5.6m |
4.3yrs
平均在職期間
56yo
平均年齢
経験豊富なボード: DOCSの 取締役会 は 経験豊富 であると考えられます ( 4.3年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/06 05:47 |
| 終値 | 2026/07/03 00:00 |
| 収益 | 2026/03/29 |
| 年間収益 | 2026/03/29 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Dr. Martens plc 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13
| アナリスト | 機関 |
|---|---|
| Richard Taylor | Barclays |
| Anne Critchlow | Berenberg |
| David Roux | BofA Global Research |